NEW YORK, NY--(Marketwire - Feb 19, 2013) - After careful analysis, Stock House Group, a research and content development investor relations firm, has initiated coverage and placed a Speculative Buy Rating on Nuvilex, Inc. (
A full Research Report accompanies the Rating placed on the Company. Stock House Group heavily weighed the Company's live cell encapsulation technology, results from Phase II cancer trials, its future late stage clinical trial, and its recent move into the medical marijuana sector and has written a comprehensive report to support the Rating.
Nuvilex, Inc. is focused on treatments in three areas -- cancer, diabetes and stem cells with its live cell encapsulation technology.
After two successful Phase I/II Clinical Trials using the company's unique and proprietary technology, the Company is currently preparing for a large scale late stage Phase III Trial.
Nuvilex recently announced a new subsidiary, Medical Marijuana Sciences, Inc., which will focus initially on developing treatments for brain cancers, including glioblastoma multiforme, that are based on cannabinoids.
About Stock House Group
Stock House Group is a full service Investment Relations firm specializing in Awareness, Research, and Content Development. The firm offers a platform that allows CEO's to tell their story through the press, Research Reports, and CEO Interviews. At the same time, Stock House Group is building a library of Research for Investors to use allowing them to get more informed on small cap stocks.
About Nuvilex, Inc.
Nuvilex, Inc. has been a provider of all-natural products for many years. The company has expanded to increase its natural product-based footprint and will continue to make advances as it moves forward. Nuvilex is an international biotechnology provider of live, therapeutically valuable, encapsulated cells and services for research and medicine. New developments by the company and its subsidiaries will be substantial as they have been working on many fronts to move Nuvilex forward. The Company's offerings will ultimately include cancer, diabetes and other treatments using the Company's natural product knowledge, product base, cell and gene therapy expertise, and live-cell encapsulation technology in addition to other new products currently under development.